Biography
Dr. Spellman works at the boundaries of basic discovery and implementation science for cancer precision medicine. He broadly collaborates to develop and deploy new analytic approaches to improve outcomes for patients with, or at high risk for, cancer. Prior to joining UCLA Dr. Spellman was Professor of Molecular and Medical Genetics at Oregon Health Science University and a Special Assistant to the Deputy Director of the NCI.

Talk
Effectiveness of Population Screening for Inherited Cancer Syndromes
Comparative Analysis of Heritable Cancer Syndrome Testing in Different Cohorts: Effectiveness, Adherence, Efficiency, and Cost-Effectiveness

Genomic Profiling Showcase:
UCLA
UCLA is the #1 ranked public research University

Biography
Bob Cook joined Castle Biosciences in 2011 and currently serves as Senior Vice President, Research & Development. Dr. Cook joined Castle Biosciences following a postdoctoral fellowship at Baylor College of Medicine, where he focused on the genetic regulation of rare ovarian granulosa cell tumors. In his current position, Dr. Cook oversees research and development at Castle. He previously completed his doctoral work in biochemistry, molecular biology and cellular biology at Northwestern University, with a focus on the structural characteristics of protein hormones important for regulating the reproductive system. He received a B.S. degree in molecular biology from Temple University in Philadelphia. Dr. Cook is an author of many medical and scientific publications and a co-inventor of several of Castle Biosciences' technologies.

Talk
Improving Patient Care and Outcomes Using Advanced Genomics
Advanced molecular diagnostics are shifting the treatment paradigm for patients with cancers by enabling personalized and risk-aligned disease management decisions. This talk will explore the potential of genomic testing in skin cancers to guide more informed patient care decisions that can improve patient outcomes.

Genomic Profiling Showcase:
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions.

Biography
Solomon Endlich is a physicist making waves in biotechnology. He spun Base5 Genomics out of his postdoctoral work on genome sequencing in the Morrison lab at Stanford University. He has over 10 years of research experience in theoretical physics and molecular biology. Solomon is passionate about solving challenging issues that have the power to propel us into the next era of precision medicine. When he isn't in the lab you can find him climbing in Yosemite, scuba diving in Monterey, or chasing his deaf rescue dog Silas around Palo Alto.

Talk
Powering Precision Medicine with Panimmunogenomic Reference Graphs
Precision medicine requires precision genomics, especially in the most clinically relevant, polymorphic, and previously unresolved immunogenomic regions like the MHC. Base5 Genomics has created the most complete panimmunogenomic reference graphs comprising full-length, fully contiguous, and haplotype-phased sequences of the MHC and other immunogenomic regions. Immediate applications are discussed.

Genomic Profiling Showcase:
Base5 Genomics
Base5 Genomics' immunogenomic platform is leading precision medicine into a new era. Base5 delivers contextualized biological ground truth with patient-specific genomic references that capture the most challenging and clinically important regions of the human genome.

Biography
Varun Dwaraka is a bioinformatics researcher specializing in epigenetics and machine learning. He leads a team at TruDiagnostic which implements machine learning methods to identify epigenetic biomarkers, and generate predictive algorithms, which help understand the molecular biology of aging. These tools are then used to investigate associations of aging to an individual's disease, and overall mortality, risk. His work has been published in numerous peer reviewed publications, and has been patented. His work has been featured in periodicals (e.g., Forbes), documentaries (e.g., HBO and Netflix), and podcasts (e.g., Alldus International). In 2020, Dr. Dwaraka was elected as a full member to the Sigma Xi, The Scientific Research Honor Society, and served as a 2023 Foresight Fellow in Biotechnology and Health Expansion, awarded by the Foresight Institute. He also serves on Scientific Advisory Boards for various entities (e.g., SRW Labs) to which he offers insight into the application and interpretation of epigenetic age biomarkers.

Talk
Developing the Most Predictive and Clinically Informative Biological Clock
Increasing biological age is the biggest risk factor for chronic disease and death; therefore, accurate prediction of biological age is imperative to understand how therapeutics affect the aging process. This presentation will showcase our efforts using MLAI on multiomics to develop biological age predictors exhibiting significant clinical utility, which revolutionize patient care and longevity research.

Genomic Profiling Showcase:
TruDiagnostic
TruDiagnostic is a revolutionary epigenetics company which seeks to help people to better understand their aging and longevity health by accessing insight from their epigenome. TruDiagnostic also research & develop epigenetic analysis methods in the effort to create new methylation-based medical diagnostic tools.

Biography
Dr. Noura Abul-Husn leads 23andMe's clinical strategy to integrate consumer genetics into healthcare. In addition to her leadership role at 23andMe, she is an Associate Professor at the Icahn School of Medicine at Mount Sinai. Dr. Abul-Husn is a physician scientist and expert in personalized healthcare and genomic medicine. She was the founding Chief of the Division of Genomic Medicine and Clinical Director of the Institute for Genomic Health at Mount Sinai, overseeing multidisciplinary teams of clinicians and researchers to spearhead genomic research, education, and care delivery innovation. Prior to that, she served as Director of Translational Genetics at the Regeneron Genetics Center. She is the recipient of numerous awards and has spoken and published extensively on her research spanning genomic discovery, genomic medicine, and health equity. Dr. Abul-Husn is a double board-certified Internist and Medical Geneticist. She completed her MD, PhD, and residency at Mount Sinai in New York.

Talk
From Consumer Genetics to Improving Health
23andMe is a consumer genetic testing company with over 14 million consumers. This session outlines the direct-to-consumer approach to communicate health-related genetic information and efforts to improve access to genetics-informed healthcare. We describe a new initiative, Total Health, that includes exome sequencing, lab testing, and telehealth consultations for personalized prevention.

Genomic Profiling Showcase:
23andMe
23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future.

Biography
Dr. Alex Hastie has committed the last 12 years of his career to bringing a novel technique, optical genome mapping (OGM), into everyday use as a key tool for understanding the genome. Alex works closely with the clinical genomics community, to help them demonstrate the value of OGM for the sensitive assessment of structural variants in germ line and somatic genomes and their role in disease and treatment opportunities. These highly rewarding relationships have resulted in dozens of publications on optical genome mapping in genomics, human research, clinical research, and cell and gene therapy.

Talk
Revolutionizing Cytogenetics Through Optical Genome Mapping
Cytogenetics has remained the standard practice for clinical genetic testing. This is because of the early realization that structural variants are a hallmark disease. Optical genome mapping is a technique that is revolutionizing cytogenomics and unlocking the understanding of structural variants in the genome at a level never seen before.

Genomic Profiling Showcase:
Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.